GLP-1 Titration Scheduler

GLP-1 receptor agonists require gradual dose titration to minimize gastrointestinal side effects (nausea, vomiting, diarrhea) that are common at treatment initiation. Titration allows the body to adapt to the drug's effects on gastric motility and appetite signaling.

This tool generates schedules based on the following FDA prescribing information and trial data:

• Semaglutide (Wegovy) — FDA Prescribing Information, Novo Nordisk. 0.25 mg → 0.5 → 1.0 → 1.7 → 2.4 mg weekly, escalating every 4 weeks.
• Semaglutide (Ozempic) — FDA Prescribing Information, Novo Nordisk. 0.25 mg → 0.5 → 1.0 mg weekly (optional 2.0 mg), escalating every 4 weeks.
• Tirzepatide (Mounjaro) — FDA Prescribing Information, Eli Lilly. 2.5 mg → 5 → 7.5 → 10 → 12.5 → 15 mg weekly, escalating every 4 weeks.
• Liraglutide (Saxenda) — FDA Prescribing Information, Novo Nordisk. 0.6 mg → 1.2 → 1.8 → 2.4 → 3.0 mg daily, escalating weekly.
• Retatrutide — Jastreboff et al., NEJM 2023, Phase 2 trial protocol. 1 mg → 2 → 4 → 8 → 12 mg weekly, escalating every 4 weeks.

The "slow titration" option doubles the duration of each non-maintenance step. This is sometimes used for patients with pronounced GI sensitivity, at the discretion of the prescriber.

This tool generates standard manufacturer-recommended titration schedules. It does not account for:

• Individual patient tolerance or contraindications
• Concomitant medications or drug interactions
• Renal or hepatic impairment
• Prior GLP-1 agonist exposure
• Prescriber-directed modifications to the schedule

Always follow your prescriber's instructions. If they provide a different titration schedule, use theirs rather than this tool's output.